RET

RET (REarranged during Transfection) is a transmembrane receptor tyrosine kinase that is activated by a complex consisting of a soluble glial cell line-derived neurotrophic factor (GDNF) family ligand (GFL) and a glycosyl phosphatidylinositol-anchored co-receptor, GDNF family receptors alpha (GFRalpha).

RET signalling is crucial for the development of the enteric nervous system. RET regulates the development of sympathetic, parasympathetic, motor, and sensory neurons, and is necessary for the postnatal maintenance of dopaminergic neurons. RET also plays a role as a driver oncogene in a variety of human cancers. Fusion of RET with several partner genes has been detected in papillary thyroid, lung, colorectal, pancreatic, and breast cancers, and tyrosine kinase inhibitors (TKIs) for RET (particularly RET-specific inhibitors) show promising effects against such cancers.

RET Inhibitors & Agonists

AD80

Cat. No.: HY-101963

AD80, a multikinase inhibitor, inhibits **RET**, **RAF**,**SRC**and **S6K**, with greatly reduced mTOR activity.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Amuvatinib

(MP470; HPK 56)

Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride)

Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

AST 487

(NVP-AST 487)

Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with IC_{50} of 520 nM.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BBT594

(NVP-BBT594)

Cat. No.: HY-18840

BBT594 is a potent **receptor tyrosine kinase RET inhibitor**, used for cancer treatment.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BT-13

Cat. No.: HY-124401

BT-13 is a potent and selective **glial cell line-derived neurotrophic factor (GDNF) receptor RET** agonist independently of GFLs, promoting neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the Rat.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Enbezotinib

Cat. No.: HY-145565

Enbezotinib, an inhibitor of **RET**, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK3179106

Cat. No.: HY-100459

GSK3179106 is an orally active and selective **RET** kinase inhibitor with IC_{50}s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity.



Purity: 99.40%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Ilorasertib

(ABT-348)

Cat. No.: HY-16018

Ilorasertib (ABT-348) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 50 mg, 100 mg

Ilorasertib hydrochloride

(ABT-348 hydrochloride)

Cat. No.: HY-16018A

Ilorasertib (ABT-348 hydrochloride) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: 99.67%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

JNJ-38158471

Cat. No.: HY-18317

JNJ-38158471 is a well tolerated, orally available, highly selective **VEGFR-2** inhibitor, with an IC_{50} of 40 nM. JNJ-38158471 also inhibits **Ret** and **Kit** with IC_{50}s of 180 and 500 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenvatinib

(E7080) Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib mesylate

(E7080 mesylate) Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib-d4

(E7080-d4) Cat. No.: HY-10981S

Lenvatinib-d4 (E7080-d4) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenvatinib-d5

(E7080-d5) Cat. No.: HY-10981S1

Lenvatinib-d5 (E7080-d5) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML786 dihydrochloride

Cat. No.: HY-14979A

ML786 dihydrochloride is a potent and orally bioavailable **Raf** inhibitor, with IC_{50}s of 2.1, 4.2, and 2.5 nM for ^{V600E}**ΔB-Raf**, **wt B-Raf**, and **C-Raf**, respectively. ML786 dihydrochloride also inhibits **Abl-1**, **DDR2**, **EPHA2**, **KDR**, and **RET** (IC_{50}=<0.5, 7.0, 11, 6.2, 0.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF 477736

(PF 00477736) Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pralsetinib

(BLU-667) Cat. No.: HY-112301

Pralsetinib (BLU-667) is a highly potent, selective **RET** inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC_{50}s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Pz-1

Cat. No.: HY-U00437

Pz-1 is a potent **RET** and **VEGFR2** inhibitor with IC_{50}s of less than 1 nM for both wild type kinases.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Regorafenib

(BAY 73-4506) Cat. No.: HY-10331

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1**, respectively.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib Hydrochloride

(BAY 73-4506 hydrochloride) Cat. No.: HY-13308

Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib monohydrate

(BAY 73-4506 monohydrate) Cat. No.: HY-10331A

Regorafenib monohydrate (BAY 73-4506 monohydrate) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib-13C,d3

(BAY 73-4506-13C,d3) Cat. No.: HY-10331S1

Regorafenib-13C,d3 is the 13C- and deuterium labeled. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Regorafenib-d3

(BAY 73-4506-d3) Cat. No.: HY-10331S

Regorafenib D3 (BAY 73-4506 D3) is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET V804M-IN-1

Cat. No.: HY-136534

RET V804M-IN-1 (compound 5) is a wt-RET -selective inhibitors of **RETV804M** kinase, with an IC_{50} of 20 nM.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RET-IN-1

Cat. No.: HY-112950

RET-IN-1 is a **RET kinase** inhibitor extracted from patent WO2018071447A1, Compound Example 552, has IC_{50s} of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-10

Cat. No.: HY-143615

RET-IN-10 is a potent inhibitor of **RET**. RET loss of function mutations leads to Hirschsprung's disease, while its gain of function mutations is associated with a variety of human tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-11

Cat. No.: HY-144131

RET-IN-11 is a potent and selective **RET** inhibitor with IC_{50}s of 6.20 nM, 18.68 nM for **RET** and RET^{V804M}, respectively. RET-IN-11 shows anti-proliferation and migration activity in CCDC6-RET-driven LC-2/ad cells. RET-IN-11 induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-12

Cat. No.: HY-144030

RET-IN-12 (compound 2) is a **RET** inhibitor, with IC_{50} values of 0.3 nM and 1 nM for RET(WT) and RET(V804M), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-13

Cat. No.: HY-144029

RET-IN-13 (compound 1), a quinoline compound, is a potent **RET** inhibitor with IC_{50}s of 0.5 nM, 0.9 nM for RET (WT) and RET (V804M), respectively. RET-IN-13 has the potential for tumors or intestinal diseases related to abnormal activation of RET research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-14

Cat. No.: HY-144170

RET-IN-14 (compound 49) is a potent **RET** inhibitor with IC_{50}s of <0.51 nM, 9.3 nM, 1.3 nM, 9.2 nM, 15 nM for RET (WT), RET (G810R), RET (V804M), BTK and BTK (C481S), respectively. RET-IN-14 has the potential for tumors research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-15

Cat. No.: HY-144422

RET-IN-15 is a **rearranged during transfection (RET) kinase** inhibitor extracted from patent WO2021115457A1 compound 51. RET-IN-15 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-16

Cat. No.: HY-146710

RET-IN-16 is a potent and selective **RET** inhibitor with IC_{50}s of 3.98 nM, 8.42 nM, 15.05 nM, 7.86 nM, 5.43 nM and 8.86 nM for **RET(WT)**, **RET(M918T)**, **RET(V804L)**, **RET(V804M)**, **RET-CCDC6** and **RET-KIF5B**, respectively. RET-IN-16 has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-3

Cat. No.: HY-133553

RET-IN-3 (compound 34) is a selective **RETV804M** kinase inhibitor, with an IC_{50} of 19 nM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RET-IN-4

Cat. No.: HY-132193

RET-IN-4 is a potent, selective and orally active **RET** inhibitor with IC_{50}s of 1.29 nM, 1.97 nM, and 0.99 nM for **RET (WT)**, **RET (V804M)**, and **RET (M918T)**, respectively. RET-IN-4 exhibits better kinases selectivity against JAK2 (IC_{50} of 4.4 nM) and FLT3 (IC_{50} of 30.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-5

Cat. No.: HY-145023

RET-IN-5 is a potent **RET (rearranged during transfection)** inhibitor with an IC_{50}s of 0.4 nM and 135.1 nM for RET and VEGFR2, respectively (WO2021213476A1, compound 18).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-6

Cat. No.: HY-145024

RET-IN-6 is a potent **RET (rearranged during transfection)** inhibitor with an IC_{50} of 4.57 nM (CN113461670A, compound 321).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-7

Cat. No.: HY-141896

RET-IN-7 demonstrates potent in vitro **RET** kinase inhibition and robust in vivo efficacy in RET-driven tumor xenografts upon multiday dosing in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-8

Cat. No.: HY-143545

RET-IN-8 is a **rearranged during transfection (RET) kinase** inhibitor extracted from patent WO2021093720A1 compound I-1. RET-IN-8 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-9

Cat. No.: HY-143546

RET-IN-9 is a potent inhibitor of **RET**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RPI-1

Cat. No.: HY-101246

RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Selpercatinib

(LOXO-292)

Cat. No.: HY-114370

Selpercatinib (LOXO-292) is a **RET kinase** inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC_{50} of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively. Antineoplastic activity.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SPP-86

Cat. No.: HY-110193

SPP-86 is a potent and selective cell permeable inhibitor of **RET tyrosine kinase**, with an IC_{50} of 8 nM. SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling, also inhibits RET-induced estrogen receptorα (ERα) phosphorylation in MCF7 cells.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

TG101209

Cat. No.: HY-10410

TG101209 is a selective **JAK2** inhibitor with IC_{50} of 6 nM, less potent to **Flt3** and **RET** with IC_{50} of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

trans-Pralsetinib

(trans-BLU-667)

Cat. No.: HY-112301A

trans-Pralsetinib (trans-BLU-667) is a **rearranged during transfection (RET)** inhibitor extracted from patent US20170121312A1, Compound Example 129.



Purity: 96.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vepafestinib

Cat. No.: HY-132846

Vepafestinib (compound 6) is a RET inhibitor (extracted from patent WO2019039439).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WF-47-JS03

Cat. No.: HY-133551

WF-47-JS03 is a potent and selective **RET** kinase inhibitor with IC_{50}s of 1.7 nM and 5.3 nM for KIF5B-RET transfected Ba/F3 cells and CCDC6-RET transfected LC-2/ad lung cancer cells, respectively.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WHI-P180 hydrochloride

(Janex 3 hydrochloride;)

Cat. No.: HY-15769A

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with IC_{50}s of 5 nM, 66 nM and 4 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zeteletinib

(BOS-172738; DS-5010)

Cat. No.: HY-139590

Zeteletinib (BOS-172738; DS-5010) is an orally active, selective **RET kinase** inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zeteletinib hemiadipate

(BOS-172738 hemiadipate; DS-5010 hemiadipate)

Cat. No.: HY-139590A

Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective **RET kinase** inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg